Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 14;9(3):695-703.
doi: 10.1016/j.ncrna.2024.03.005. eCollection 2024 Sep.

miR-4716-3p and the target AKT2 Gene/rs2304186 SNP are associated with blood cancer pathogenesis in Pakistani population

Jairus Olumasai Nandwa  1   2   3 , Azhar Mehmood  1 , Ishrat Mahjabeen  1 , Kayode Yomi Raheem  1 , Mamoudou Hamadou  4 , Mouhamed Z K A Raimi  1 , Mahmood A Kayani  1
Affiliations

miR-4716-3p and the target AKT2 Gene/rs2304186 SNP are associated with blood cancer pathogenesis in Pakistani population

Jairus Olumasai Nandwa et al. Noncoding RNA Res. .

Abstract

AKT2 is crucial for cancer cells' invasion, metastasis, and survival. It is a possible downstream gene target of cancer glycolysis-related microRNAs. The study investigated the role of miRNA-4716-3p, rs2304186, and the AKT2 gene in blood cancer pathogenesis. RT-qPCR was used to analyze AKT2 gene mRNA and miRNA-4716-3p expression in 200 blood cancer samples and 200 healthy controls. Furthermore, Tetra-ARMS PCR was used to examine the rs2304186 AKT2 SNP in 300 patients and 290 control samples. miRNA-4716-3p was shown to be significantly downregulated (p = 0.0294), whereas mRNA expression of the AKT2 gene was found to be significantly upregulated (p = 0.0034) in blood cancer patients compared to healthy individuals. miRNA-4716-3p downregulation (p = 0.0466) was more pronounced, while AKT2 upregulation was non-significant (p = 0.1661) in untreated patients compared to chemotherapy-treated patients. Blood cancer risk was significantly associated with the rs2304186 GT genotype (p = 0.0432), TT genotype (p = 0.0502), and mutant allele (T) frequency (p = 0.0008). Polymorphism rs2304186 was associated with an increased risk of blood cancer in dominant (p = 0.0011), recessive (p = 0.0502), and additive (p = 0.0008) genetic models. The results suggested that the rs2304186 and the deregulated expression of miRNA-4716-3p and AKT2 gene at the mRNA level may significantly increase the incidence of blood cancer, particularly in the Pakistani population. Therefore, these may function as suitable biomarkers for blood cancer diagnosis and prognosis. Additional, larger-scale investigations may be required to affirm these results.

Keywords: AKT2; Biomarkers; Blood cancer; Polymorphism; miRNA-4716–3p.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of Interest. Thus, they approved the submission and publication of this manuscript without any reservations.

Figures

Image 1
Graphical abstract
Fig. 1
Fig. 1
miR-4716–3p and AKT2 3' UTR SNP rs2304186 can promote cancer cell apoptosis, survival, and metastasis.
Fig. 2
Fig. 2
AKT2 Association with Blood Cancer (A) AKT2 gene expression in blood cancer patients versus healthy controls (B) Relative expression of AKT2 gene in different types of blood cancer patients. (C) Relative expression of AKT2 gene in leukemia sub-types (D) Relative expression of AKT2 gene in lymphoma types.
Fig. 3
Fig. 3
Association of miRNA-4716-3p with Blood Cancer (A) Relative expression of microRNA- 4716–3p in Blood Cancer Patients and Controls (B) microRNA-4716–3p expression levels in different types of blood cancer (C) Relative expression of microRNA- 4716–3p in leukemia sub-types (D) Expression of microRNA-4716–3p in lymphoma types.
Fig. 4
Fig. 4
miR-4716–3p and AKT2 gene Diagnostic Value Analysis.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Méndez-Ferrer S., Bonnet D., Steensma D.P., Hasserjian R.P., Ghobrial I.M., Gribben J.G., Andreeff M., Krause D.S. Bone marrow niches in haematological malignancies. Nat. Rev. Cancer. 2020;20(Issue 5):285–298. doi: 10.1038/s41568-020-0245-2. Nature Research. - DOI - PMC - PubMed
    1. Arber D.A., Orazi A., Hasserjian R., Thiele J., Borowitz M.J., Le Beau M.M., Bloomfield C.D., Cazzola M., Vardiman J.W. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi: 10.1182/blood-2016-03-643544. American Society of Hematology. - DOI - PubMed
    1. Haloupek N. The landscape of blood cancer research today-and where the field is headed. Blood Cancer Discov. 2020;1:1–4. doi: 10.1158/2643-3249.BCD-20-0083. july 2020 BLOOD CANCER DISCOVERY | 1. - DOI - PMC - PubMed
    1. Idrees R., Fatima S., Abdul-Ghafar J., Raheem A., Ahmad Z. Cancer prevalence in Pakistan: meta-analysis of various published studies to determine variation in cancer figures resulting from marked population heterogeneity in different parts of the country. World J. Surg. Oncol. 2018;16(1) doi: 10.1186/s12957-018-1429-z. - DOI - PMC - PubMed
    1. Lupo P.J., Spector L.G. Cancer progress and priorities: childhood cancer. Cancer Epidemiol. Biomarkers Prev. 2020;29(6):1081–1094. doi: 10.1158/1055-9965.EPI-19-0941. - DOI - PMC - PubMed

LinkOut - more resources